SOURCE: BIOLASE, Inc.

BIOLASE, Inc.

December 30, 2013 06:00 ET

BIOLASE Granted Canadian License to Sell Its Flagship EPIC 10 Soft-Tissue Diode Laser

IRVINE, CA--(Marketwired - Dec 30, 2013) - BIOLASE, Inc. (NASDAQ: BIOL), the world's leading manufacturer and distributor of dental lasers, and a pioneer in laser surgery in other medical specialties, today announced that it has received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada. BIOLASE sells its products in Canada through a direct sales force and select distributors.

Chairman and CEO Federico Pignatelli commented, "With an estimated 19,000 dentists, Canada has historically represented one of BIOLASE's most robust markets for its high-tech laser products. We believe that there is pent-up demand for the EPIC soft-tissue diode laser in Canada from our large and loyal installed base, and this approval is an important milestone for BIOLASE. We expect the Canadian market to be a strong contributor to our growth in 2014 with the ability to sell our newly cleared flagship EPIC 10-watt soft-tissue diode laser in addition to our revolutionary WaterLase iPlus."

Tannis Sigurdson, Canada Sales Manager commented, "We are excited to have received Health Canada approval for our Epic 10 soft tissue laser. A large group of dentists and hygienists have been waiting very patiently for this approval of our newest generation of our Laser Family, and we are thrilled to add EPIC 10 to our Canadian product portfolio.

"Biolase lasers are highly regarded as state of the art systems that create superior surgical and aesthetic results within a dental practice. The Epic 10's new sleek and versatile design will just make it easier for dentists to integrate it in their practice, and the added whitening feature will offer their patients quick and easy laser bleaching in one visit. We do believe that dental lasers will be the standard of care in every dental practice."

About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment and CAD/CAM intraoral scanners and in-office milling machines; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 24,000 lasers. Other laser products under development address ophthalmology and other medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc and YouTube at www.youtube.com/biolasevideos.

BIOLASE®, WaterLase®, and EPIC™ are registered trademarks or trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

Contact Information

  • For further information, please contact:
    Michael Porter
    Porter, LeVay & Rose, Inc.
    212-564-4700